Patients and study design
Burns, bleeding, phobia, gangrene, pain, burns
SLOUGH, MAY, BLEEDING, GANGRENE
This open randomized controlled trial was carried out at Shahid Motahari Burns Hospital, Tehran, Iran, from November 2018 to May 2020. Participants were 31 cases with at least one full-thickness (grade III based on ICD-10 classifications) burn that referred to Shahid Motahari Burns Hospital related to Iran University of Medical Sciences, Tehran, Iran. The flow of participants is shown in Fig. Flow of participants enrolled in this study. The present study was conducted based on CONSORT guidelines for reporting clinical trialsAll the cases in the larvae group were informed about the methodology and study purposes and enrolled as volunteers, with a signed consent letter. Patients who had phobia or other serious per-exiting conditions including the presence of gangrene, severe pain, refractory to treatment, and immunocompromised patients (e.g., HIV/AIDS) and those who have been receiving steroids and anti-coagulants that might affect the results were excluded from the study. Furthermore, probable bleeding because of larvae therapy and causing slough burns were also considered as exclusion criteria. All the procedures were in accordance with the Helsinki Declaration regarding human research and were reviewed and approved by the Medical Ethics Board of Tehran University of Medical Sciences, Tehran, Iran (with code no. IR.TUMS.VCR.REC.1396.4691) [